Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers by He, Lei et al.
RESEARCH ARTICLE Open Access
Up-regulated expression of type II very low
density lipoprotein receptor correlates with
cancer metastasis and has a potential link to









Background: Very low density lipoprotein receptor (VLDLR) has been considered as a multiple function receptor
due to binding numerous ligands, causing endocytosis and regulating cellular signaling. Our group previously
reported that enhanced activity of type II VLDLR (VLDLR II), one subtype of VLDLR, promotes adenocarcinoma
SGC7901 cells proliferation and migration. The aim of this study is to explore the expression levels of VLDLR II in
human gastric, breast and lung cancer tissues, and to investigate its relationship with clinical characteristics and
b-catenin expression status.
Methods: VLDLR II expression was examined using immunohistochemistry (IHC) and Western blot in tumor tissues
from 213 gastric, breast and lung cancer patients, tumor adjacent noncancerous tissues by same methods.
Correlations between VLDLR II and clinical features, as well as b-catenin expression status were evaluated by
statistical analysis.
Results: The immunohistochemical staining of VLDLR II showed statistical difference between tumor tissues and
tumor adjacent noncancerous tissues in gastric, breast and lung cancers (P = 0.034, 0.018 and 0.043, respectively).
Moreover, using Western, we found higher VLDLR II expression levels were associated with lymph node and distant
metastasis in gastric and breast cancer (P < 0.05). Furthermore, highly significant positive correlations were found
between VLDLR II and b-catenin in gastric cancer (r = 0.689; P < 0.001)breast cancer (r = 0.594; P < 0.001).
Conclusions: According to the results of the current study, high VLDLR II expression is correlated with lymph node
and distant metastasis in gastric and breast cancer patients, the data suggest that VLDLR II may be a clinical
marker in cancers, and has a potential link with b-catenin signaling pathway. This is the first to reveal the closer
relationship of VLDLR II with clinical information.
Background
The very low density lipoprotein receptor (VLDLR) which
belongs to the low density lipoprotein receptor (LDLR)
family was initially cloned on the basis of its homology to
the LDLR [1]. This receptor exhibits domain structures
similar to those of the LDLR, except it has an extra repeat
of the cysteine-rich ligand-binding domain. The tissue dis-
tribution of VLDLR is most abundantly expressed in heart,
skeletal muscle and adipose tissue [2], the VLDLR is ori-
ginally considered to specifically bind to VLDL and played
important roles for apolipoprotein E (apoE) metabolism.
Interest in VLDLR has focused mainly on its possible role
in extrahepatic tissues active in fatty acid metabolism and
its role as an energy source [3]. However, the physiological
and pathological importance of this receptor has not been
clearly identified. Previous studies has found that VLDLR
is a multiple function receptor due to binding numerous
ligands besides lipoproteins, including lipoprotein lipase
(LPL), receptor-associated protein (RAP), thrombospon-
din-1, urokinase plasminogen activator/plasminogen
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other proteinase-serpin complexes, causing endocytosis
and affecting many cellular functions [4-8].
Furthermore, a signaling function for the VLDLR has
also been recognized, as demonstrated by the ability of
reelin to modulate neuronal migration, neurodevelop-
ment, and other physiological processes in the central
nervous system. Binding of reelin to VLDLR induces
tyrosine phosphorylation of Disable-1 (Dab-1) in neu-
rons [9]. In addition to neuronal migration via reelin,
in vitro studies revealed that the VLDLR modulates cell
migration via a pathway that depends on uPA [10]. That
receptor-bound uPA plays a pivotal role in tumor inva-
sion and metastasis via the generation of plasmin and
subsequent degradation of the extracellular matrix in
various processes like cancer cell invasion, stromal
remodelling, and angiogenesis [11]. So the VLDLR
appears to regulate biological processes by binding or
internalization of ligands, or by transducing extracellular
signals across the cell membrane.
VLDLR consists of two subtypes because of alternative
splicing, namely the full-length VLDLR and type II
VLDLR (VLDLR II) which lacks the O-linked sugar
domain encode by the 16th exon. The tissue distribution
of two VLDLR subtypes are different, the full-length
VLDLR mainly expressed in heart and muscles with
high lipid metabolism, whereas VLDLR II is a ~ 105
kDa protein that mainly expressed in kidney, spleen,
adrenal gland and testis [12]. The previous research has
also shown that VLDLR II is predominantly expressed
in the gastroenterological cancer, breast cancer, lung
cancer and so on [13]. Other report indicates that the
O-linked sugar domain of VLDLR has been demon-
strated to be responsible for cell growth inhibition, and
this growth inhibition is ligand-independed [14]. These
studies suggest that VLDLR II activities may be related
to certain cellular functions other than its involvement
in lipoprotein metabolism, and has been speculated to
promote the tumor cells to proliferate and metastasis.
b-catenin is part of the cadherin-catenin complex that
mediates cell-cell adhesion [15] and is a critical member
of the canonical Wnt signaling pathway that is active
normally in embryogenesis. It also is believed that aber-
rant Wnt signaling is a characteristic shared by numerous
human tumors [16]. Recent studies have revealed that
Wnt signal transduction plays a pivotal role in human
tumor development, where it mediates the transcription
of numerous downstream target genes associated with
increased growth and invasion [17]. Chen et al reported
that VLDLR is a negative regulator of the Wnt signaling
pathway [18]. But in the past research, we have indicated
that increased b-catenin accumulation is found in the
human gastric adenocarcinoma cell line SGC7901,
accompanied by an increase in VLDLR II expression.
These previous results suggest that the molecular
mechanism underlying the role of VLDLR II in tumor
cell proliferation and migration may be related to the sta-
bility of b-catenin and the subsequent activation of the
transcription of certain target genes. However, in tumor
tissue levels, whether the mount of b-catenin has a corre-
lation with VLDLR II expression need to be elucidated.
In the current study, we examined the expression of
VLDLR II in different carcinoma samples by immuno-
histochemistry (IHC) and Western blot, and investigated
whether the expression of VLDLR II are different
between normal and malignant tissues. Then we further
analyzed potential correlations of VLDLR II expression
levels with various clinicopathologic tumor features, as
well as with b-catenin expression levels.
Methods
Clinical cancer specimens
213 clinical specimens from gastric, breast and lung can-
cer patients who had undergone surgical resection (start-
ing from 2008) at the department of surgery, both of
Tongji Hospital and Union Hospital (Wuhan, China),
were investigated in this study. Informed consent was
obtained from patients for their tissues to be used in
research. For each patient, a sample of adjacent and
apparently non-affected tissue was also taken and used as
normal control. The histological diagnosis of each tumor
was confirmed on the hematoxylin and eosin-stained sec-
tions. Pathologic tumor, lymph node, metastasis (TNM)
status were assessed in all patients according to the TNM
classification system of the International Union Against
Cancer/American Joint Committee on Cancer (UICC/
AJCC). In order to ensure reliable results, we divided
above-mentioned cancer samples into two groups, one
group was comprised of 22 gastric cancers, 18 breast can-
cers, and 24 lung cancers, they were fixed in formalin and
embedded in paraffin for IHC. Another group also con-
sists of surgical specimens of gastric, breast, and lung
cancers (52, 46, 51, respectively), and were snap-frozen
immediately after resection using liquid nitrogen and
stored at -80°C until used for Western blot analysis. The
choice and grouping of all samples were based on blind
election and random principle. All patients gave
informed consent to use excess pathological specimens
for research purposes. Research was carried out in com-
pliance with Helsinki Declaration with the approval of
the Ethics Committee of Tongji Medical College (Email:
tongjilunli@163.com).
Antibodies
The monoclonal antibody against VLDLR II was pre-
pared as previously described [19], which could be
applied for IHC and Western blot examination. The
mouse monoclonal anti-human b-catenin was obtained
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body against b-actin was purchased from Santa Cruz
Biotechnology (CA, USA).
Immunohistochemistry methods
Antibody staining was performed on 4-μm histological
sections of formalin-fixed, paraffin-embedded tumor and
adjacent normal samples. Serial 4-μm sections were
mounted on pretreated glass slides, deparaffinized, rehy-
drated, and microwaved for 15 minutes at high power in
10 mmol/L citrate buffer (pH 6.0) to unmask the epi-
topes. Endogenous peroxidase was quenched using 3%
H2O2 for 10 minutes; slides were then washed in phos-
phate-buffered saline (PBS, pH 7.5) and incubated with
the 5% bovine serum albumin (BSA) for 20 minutes.
Sections were incubated overnight at 4ºC with a 1:100
dilution of anti-VLDLR II antibody described above.
After washing, the sections were incubated with horse-
radish peroxidase-conjugated secondary antibodies for 1
hour at room temperature. After washing, tissues were
stained for 5 minutes with DAB (3, 3’-diaminobenzidine)
chromogen and counterstained with hematoxylin, dehy-
drated, and coverslipped. Each experiment was per-
formed in duplicate. Mean values from repeated counts
were recorded for each case.
Evaluation of immunohistochemistry
For each spot, areas of most intense and/or predominant
staining pattern were scored by eye. Immunostaining pat-
tern for each case was independently evaluated by two
investigators (YJL and PW) at a two-headed microscope.
VLDLR II expression was classified according to the fol-
lowing grading system: staining intensity was categorized
as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong).
Staining areas were categorized as 0 (no positive cells),
0.1 (≤ 25% positive cells), 0.4 (> 25% and ≤ 50% positive
cells), 0.6 (> 50% and ≤ 75% positive cells), or 0.9 (> 75%
positive cells). To gauge both stain intensity and unifor-
mity simultaneously, the average values for intensity for
each tissue were multiplied by the average values for per-
centage area stained in each tissue to derive a composite
histoscore (i.e., histoscore = area × intensity). A tissue
with intense, uniform staining would be assigned the
maximum histoscore of 2.7, whereas a tissue with light
staining intensity (a value of 1) in only > 25% and ≤ 50%
of the tissue (a value of 0.4) would get a histoscore of 0.4.
Assigning a histoscore is now a commonly used method
for evaluating both stain uniformity and intensity in tis-
sues to better relate results between multiple samples
from immunohistochemical studies [20].
Western blot analysis
Prior to immunoblotting, tissues were washed three
times with ice cold PBS, homogenized in lysis buffer
(1% NP-40, 50 mmol/L Tris, pH 7.5, 5 mmol/L EDTA,
1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1
mmol/L PMSF, 10 mg/mL aprotinin, and 1 mg/mL
leupeptin) and then incubated for 20 minutes at 4°C
while rocking. Lysates were cleared by centrifugation
(10 min, 12 000 rpm, 4°C). 100 μg of total protein was
resolved by 10% SDS-PAGE and transferred onto
nitrocellulose membranes (Immbilon, Millipore). The
membranes were blocked with 5% nonfat dry milk for
2 hours at room temperature, and then incubated
overnight at 4°C with first antibodies which were
against VLDLR II, b-actin or b-catenin. After washing
the membranes 3 times with TBST (50 mmol/L
Tris-HCL pH7.6, 150 mmol/L NaCl, 0.1% Tween 20),
membranes were incubated with horseradish peroxi-
dase-conjugated secondary antibodies for 1 hour at
room temperature according to the manufacturer’s
instructions. The membranes were washed 3 times
with TBST. Detection of immunocomplexes was per-
formed with an enhanced chemiluminescence system
(NEN Life Science Products, Boston, MA), the values
were normalized to b-actin expression, and the level of
protein expression determined using Image Quant TL
software (Amersham Pharmacia Biotech, Piscataway,
USA).
Statistical analysis
The difference of VLDLR II expression between tumor
and paired normal tissues were assessed using the stu-
dent t-test for paired values, both IHC and Western blot
data were used to establish this diversities. The Mann-
Whitney test or Kruskal-Wallis test (for > 2 groups)
were used to analyze the association between expression
levels of VLDLR II and clinical parameters. The direc-
tion and the strength of association between VLDLR II
and b-catenin were evaluated and compared with the
Spearman correlations test. Data were reported as mean
±S D ,P value < 0.05 was considered statistically signifi-
cant. All statistical analyses were performed with Super-
ior Performance Software System (SPSS) 15.0 for
Windows (SPSS Inc, Chicago, IL).
Results
Detection of cellular VLDLR II expression by IHC staining
of cancer tissues
Using IHC, we examined the distribution of VLDLR II
protein in parraffin-embedded mammary tissue sections
screened from gastric, breast and lung cancer patients
(22, 18, and 24, respectively). VLDLR II was mainly
localized in the cytomembrane of either tumor or nor-
mal cell (Figure 1). Here, the level of VLDLR II expres-
sion refers to the histoscore of cells within each tissue
sample that stained positively for the special antibody,
and the evaluation scoring system had been described
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positively stained, and their percentage within the tissue
was determined. Comparison between tumor and nor-
mal tissue revealed that VLDLR II expression levels
were significantly increased in gastric, breast and lung
cancer patients (P = 0.034, 0.018, and 0.043, respectively;
Figure 2). Moreover, we observed a tissue specific profile
of VLDLR II protein expression both in tumor and nor-
mal tissues, with highest levels of expression in breast
cancer, followed by gastric and lung cancer. The histo-
score of VLDLR II staining from different cancers were
summarized in Table 1.
Figure 1 VLDLR II detection by IHC. Representative Immunohistochemical staining of VLDLR II protein in paraffin-embedded human different
cancers and matched adjacent noncancerous tissues. A, B: Gastric normal and tumor tissue; C, D: Breast normal and tumor tissue; E, F: Lung
normal and tumor tissue. VLDLR II staining show predominantly membranous localization, and a much smaller subset also showed cytoplasmic
staining. Normal tissues seen in A, C, E are weak-to-moderate stained, while in cancer cells, VLDLR II staining are strongly intense (B, D, F).
Original magnification: × 200; × 400 (insets).
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difference cancer tissues
In order to verify the IHC results and further assess
VLDLR II expression whether correlates with clinical
information, the cancer specimens and paired non-
infected tissues from gastric, breast and lung cancer
patients (52, 46 and 51, respectively) were analyzed by
Western blot to quantitatively assess the proteins inves-
tigated. The values were normalized to b-actin expres-
s i o n .A ss h o w ni nT a b l e1 ,V L D L RI Iw a sd e t e c t e di n
cancer tissues at significantly higher levels than in the
normal tissues from gastric and breast cancers (P =
0.003, 0.001), both results paralleled IHC data. But no
significant differences were found in lung caners (P =
0.073).
VLDLR II protein in gastric cancer tissues
We assessed the expression level of VLDLR II in gastric
cancer tissues and matched adjacent normal tissues via
Western blot analysis. Figure 3A illustrated VLDLR II
expression in 8 representative gastric cancer patients.
Through statistical analysis with relative protein expres-
sion levels of VLDLR II in gastric cancer tissues from 52
patients, as shown in box graph, we found that VLDLR
II expression was significantly elevated in gastric cancers
in comparison to the matched normal adjacent tissues,
this result was consistent with which obtained via IHC.
In addition, VLDLR II expression in cancer tissues was
not significantly associated with age, gender, tumor size
or histological grade. But elevated VLDLR II expression
was associated with lymph node metastasis (P =0 . 0 1 3 )
and a higher expression was noted in patients with dis-
tant metastasis (P =0 . 0 0 4 )a n da d v a n c e dT N Ms t a g e
group (P = 0.011). Because VLDLR II played role for
lipid metabolism, we also analysed the relationship
between VLDLR II expression and other clinical features
including body weight and plasma lipid profiles. The
results shown that VLDLR II expression in cancer tis-
sues was not significantly associated with body weight,
total cholesterol (TC) and triglycerides (TG) (Table 2).
VLDLR II protein in breast cancer tissues
We classified 46 patients with breast cancer, according
to the TNM stage, histological grade, plasma lipid pro-
files and the levels of total VLDLR II protein in each
subgroup. Significant increases in VLDLR II protein
Figure 2 The histoscore of VLDLR II staining in gastric (A), breast (B), lung (C) cancers and in the paired non-affected ones. Statistical
analysis with histoscore (area stained multiplied by intensity) of VLDLR II in tissues from gastric, breast and lung cancer patients (22, 18, and 24,
respectively). VLDLR II expression levels are significantly higher in tumors compared with normal tissues (P = 0.034, 0.018, and 0.043, respectively).
Abbreviations: N, matched adjacent normal tissue; T, tumor tissue.





(Ratio of VLDLR II/b-
actin)
N mean SD. P N Mean SD. P
Gastric cancer 22 52
Normal tissue 22 0.80 0.67 0.034* 52 0.78 0.26 0.003*
Cancer tissue 22 1.10 0.53 52 0.93 0.40
Breast cancer 18 46
Normal tissue 18 0.81 0.54 0.018* 46 0.93 0.43 0.001*
Cancer tissue 18 1.24 0.77 46 1.10 0.48
Lung cancer 24 51
Normal tissue 24 0.68 0.50 0.043* 51 0.57 0.19 0.073
Cancer tissue 24 0.97 0.67 51 0.61 0.21
Statistical analyses were performed by Paired Students’ t test (2-tailed).
* P < 0.05 is considered significant.
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patients studied (Figure 3B). As shown in Table 3, not
only a global increase of VLDLR II in cancer tissues in
comparison to their paired adjacent non-affected tissue,
but also the higher expression of VLDLR II is associated
with lymph node metastasis, distant metastasis and
poorly differentiated (P = 0.003, 0.007 and 0.043, respec-
tively). With regard to TNM stage, the difference is sta-
tistically significant with stage III-IV group and stag I-II
group (P = 0.027), whereas in age, body weight, TC, TG,
and tumor size, it was not.
VLDLR II protein in lung cancer tissues
In a group of 51 patients affected by lung cancer, as shown
in Figure 3C, the comparison between normal and cancer
tissues did not indicate significant difference in expression
of VLDLR II protein, this result was different with which
obtained via IHC (Table 1). However, to gain better insight
into the expression level of VLDLR II in histological types
of lung cancer, we analysed the difference expression of
VLDLR II between normal and cancer tissues in 4 histolo-
gical types of lung cancer (18 adenocarcinomas, 24 squa-
mous carcinomas, 6 small cell lung carcinomas, and 3
adeno-squamous carcinomas). The expression of VLDLR
II was significantly elevated in adenocarcinoma tissues in
comparison to the corresponding adjacent non-affected
tissues (P = 0.048), whereas in other histological types, it
was not (Table 4). When analyzing expression levels of
VLDLR II associated with common clinical features, we
found the difference was statistically significant only in
patients with distant metastasis (P = 0.008). Clinical vari-
ables were summarized in Table 5.
Correlation between VLDLR II protein and b-catenin
expression levels in different cancers
In previous study, we had found that increased b-catenin
accumulated in the SGC7901 cell line, accompanied by
Figure 3 Western blot analysis of VLDLR II expression from normal and tumor samples. 100 μg of total protein extracted from tumor
tissues and matched adjacent noncancerous tissues were tested by Western blot. A-C: Some representative samples from gastric, breast, and
lung cancer patients (8 for each), indicate as N and T for normal and tumor samples. VLDLR II expression levels are higher in gastric and breast
tumor tissues compared with matched adjacent noncancerous tissues (A, B). In lung tumor tissues, VLDLR II is either high or similar as compared
with normal tissues (C). The same filter membranes were probed with b-actin. The bands were densitometrically scanned and referred to b-actin
as internal control. The box graphs are shown the statistical analysis with relative protein expression levels of VLDLR II in tissues from gastric,
breast, and lung cancer patients (52, 46, and 51, respectively). Abbreviations: N, normal tissue; T, tumor tissue.
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study, we further examined whether the VLDLR II
expression could be correlated with b-catenin in tissue
levels from different cancers. Except for evaluating
VLDLR II expression in different cancer tissues, we also
detected b-catenin in same cancer specimens and adja-
cent normal tissues by Western blot. b-catenin expres-
sion levels were different between normal and tumor
tissues from gastric, breast, and lung cancer patients (Fig-
ure 4A). Next, we evaluated the correlation between
VLDLR II and b-catenin expression, as a result, Figure
4B and 4C illustrated that highly significant positive cor-
relations were found between VLDLR II and b-catenin in
gastric cancers (Spearman test: r = 0.689; P < 0.001) and
breast cancers (Spearman test: r = 0.594; P < 0.001),
whereas b-catenin expression didn’tc o r r e l a t e dw i t h
VLDLR II expression in lung cancers (Spearman test:
r = 0.222; P = 0.118; Figure 4D).
Discussion
VLDLR is a member of the LDLR family [1], which
includes the LDLRs, LDL receptor-related protein (LRP)
and so on. These receptors have equivalent structural
motifs and band many of same ligands [22]. And now,
VLDLR and the other members of LDLR are known as
the multifunctional receptor like “Swiss army knife” [23].
It is widely believed that the LDL receptor family partici-
pated in the tumorigenesis, which the receptor mediated
endocytosis has been as a way to regulate the tumor cell
migration [24]. For example, LRP mediates the endocyto-
sis of uPAR through an indirect mechanism that depends
on uPA/PAI-1 complex, and then regulates the activity of
uPA/uPAR system within cancer cells [25]. Similarly,
Table 2 Correlation between VLDLR II expression and
clinical features in 52 gastric cancer patients
Parameters Number VLDLR II fold P
Age at diagnosis
≥ 60 years 26 1.34 ± 0.58 0.133
< 60 years 26 1.19 ± 0.55
Gender
Male 37 1.28 ± 0.58 0.709
Female 15 1.22 ± 0.55
Body weight
≥ 60 kg 17 1.14 ± 0.31 0.565
< 60 kg 35 1.33 ± 0.65
TC
> 5.20 mmol/L 11 1.11 ± 0.20 0.662
≤ 5.20 mmol/L 41 1.31 ± 0.62
TG
> 1.70 mmol/L 9 1.02 ± 0.23 0.204
≤ 1.70 mmol/L 43 1.32 ± 0.60
Histological grade
Well to moderately differentiated 30 1.19 ± 0.55 0.165
Poorly differentiated 22 1.37 ± 0.58
Tumor size
≥ 5 cm 25 1.40 ± 0.60 0.087
< 5 cm 27 1.14 ± 0.51
Lymph node metastasis
Negative 15 1.02 ± 0.51 0.013*
Positive 37 1.35 ± 0.56
Distant metastasis
Negative 41 1.13 ± 0.41 0.004*
Positive 11 1.78 ± 0.77
TNM stage
Stage I-II 22 1.08 ± 0.46 0.011*
Stage III-IV 30 1.40 ± 0.60
Folds (VLDLR II protein in tumor/in normal) in mean ± SD, VLDLR II measured
by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG,
triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were
performed by Mann-Whitney test.
*P< 0.05 is considered significant.
Table 3 Correlation between VLDLR II expression and
clinical features in 46 Breast cancer patients
Parameters Number VLDLR II fold P
Age at diagnosis
≥ 50 years 29 1.30 ± 0.44 0.820
< 50 years 17 1.28 ± 0.40
Body weight
≥ 50 kg 19 1.38 ± 0.39 0.080
< 50 kg 27 1.21 ± 0.43
TC
> 5.20 mmol/L 7 1.09 ± 0.34 0.178
≤ 5.20 mmol/L 39 1.31 ± 0.42
TG
> 1.70 mmol/L 13 1.15 ± 0.28 0.360
≤ 1.70 mmol/L 33 1.33 ± 0.45
Histological grade
Well to moderately differentiated 28 1.18 ± 0.36 0.043*
Poorly differentiated 18 1.43 ± 0.45
Tumor size
≥ 2 cm 21 1.34 ± 0.47 0.442
< 2 cm 25 1.22 ± 0.37
Lymph node metastasis
Negative 15 1.14 ± 0.15 0.003*
Positive 31 1.43 ± 0.45
Distant metastasis
Negative 32 1.16 ± 0.30 0.007*
Positive 14 1.52 ± 0.41
TNM stage
Stage I-II 24 1.14 ± 0.31 0.027*
Stage III-IV 22 1.41 ± 0.47
Folds (VLDLR II protein in tumor/in normal) in mean ± SD. VLDLR II measured
by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG,
triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were
performed by Mann-Whitney test.
* P < 0.05 is considered significan.
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energy source for the rapid growth of cancer cells or may
function as a modulator for cancer invasion and metasta-
sis through ligands such as uPA and its type1 inhibitor
complexes [7,26]. Webb et al. reported that VLDLR regu-
lates autocrine uPAR-initiated signaling and thereby reg-
ulates MCF-7 breast cancer cell motility [27].
Alternative splicing exists in many members of LDLR
family, and there is some supportive evidence in which
lipoprotein receptor variants may be involved in differ-
ent biological processes. In the same way, VLDLR II
which lacks the O-linked sugar domain encoded by the
16th exon is emerged through alternative splicing, and
mainly expresses in kidney, spleen, adrenal gland and
testis. However, the full-length VLDLR is most highly
expressed in heart, skeletal muscle and adipose tissue
with active fatty acid metabolism [12]. It was generally
accepted that full-length VLDLR played an important
role in the metabolism of lipoprotein enriched in apoE
[1], Wada et al. had indicated that the O-linked sugar
domain of VLDLR appeared to be responsible for the
cell growth inhibition [14]. Our previous study had
found that over-expression of the full-length VLDLR
didn’t promote SGC7901 cell migration and prolifera-
tion, while the cell migration and proliferation were
increased in cells stably over-expressing VLDLR II [21].
Another report demonstrated that genetic loss of the
VLDLR gene is involved in carcinogenesis including that
of gastric carcinogenesis [28]. These studies suggest that
VLDLR II activities may be related to certain cellular
functions other than its involvement in lipoprotein
metabolism.
Most results with VLDLR II had been obtained, which
demonstrate pivotal role of this receptor associated with
cellular proliferation and migration. Nakamura et al.
reported that VLDLR II is the major receptor in the
early phase of fetal brain, which is related to brain
development [29]. Furthermore, the studies suggested
that VLDLR II and apoE receptor may induce the signal
transduction between extracellular Reelin and intracellu-
lar Dab1, which phosphorylates Dab1 and activates
intracellular kinase to affect the migration and accurate
Table 4 Expression of VLDLR II in different histological





(Ratio of VLDLR II/b-
actin)
N mean SD. P N Mean SD. P
ADCA 10 18
Normal tissue 10 0.71 0.12 0.034* 18 0.60 0.18 0.048*
Cancer tissue 10 1.29 0.71 18 0.70 0.25
SQCA 13 24
Normal tissue 13 0.68 0.68 0.651 24 0.54 0.16 0.602
Cancer tissue 13 0.75 0.58 24 0.56 0.18
SCLC 1 6
Normal tissue 1 0.4 –– 6 0.56 0.20 0.554
Cancer tissue 1 0.6 6 0.59 0.30
A-SCA 3
Normal tissue –– – –3 0.49 0.09 0.118
Cancer tissue –– 3 0.58 0.07
ADCA indicates adenocarcinoma; SQCA, squamous cell carcinoma; SCLC, small
cell carcinoma; A-SCA, adeno-squamous carcinoma. Statistical analyses were
performed by Paired Students’ t test (2-tailed).
* P < 0.05 is considered significant.
Table 5 Correlation between VLDLR II expression and
clinical features in 51 Lung cancer patients
Parameters Number VLDLR II fold P
Age at diagnosis
≥ 55 years 30 1.16 ± 0.25 0.781
< 55 years 21 1.11 ± 0.34
Gender
Male 35 1.12 ± 0.31 0.424
Female 16 1.19 ± 0.37
Body weight
≥ 60 kg 19 1.15 ± 0.22 0.823
< 60 kg 32 1.13 ± 0.32
TC
> 5.20 mmol/L 12 1.03 ± 0.20 0.096
≤ 5.20 mmol/L 39 1.16 ± 0.30
TG
> 1.70 mmol/L 9 1.01 ± 0.35 0.166
≤ 1.70 mmol/L 42 1.17 ± 0.27
Histological grade
Well to moderately differentiated 38 1.11 ± 0.29 0.133
Poorly differentiated 13 1.25 ± 0.27
Tumor size
≥ 5 cm 22 1.20 ± 0.30 0.254
< 5 cm 29 1.09 ± 0.28
Lymph node metastasis
Negative 15 1.01 ± 0.37 0.090
Positive 36 1.19 ± 0.23
Distant metastasis
Negative 40 1.06 ± 0.26 0.008*
Positive 11 1.36 ± 0.29
TNM stage
Stage I-II 25 1.06 ± 0.27 0.061
Stage III-IV 26 1.25 ± 0.29
Histological type
adenocarcinoma 18 1.22 ± 0.29 0.190
squamous cell carcinoma 24 1.11 ± 0.31
small cell carcinoma 6 1.03 ± 0.19
adeno-squamous carcinoma 3 1.09 ± 0.07
Folds (VLDLR II protein in tumor/in normal) in mean ± SD. VLDLR II measured
by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG,
triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were
performed by Mann-Whitney test (for 2 groups) or Kruskal-Wallis test (for > 2
groups).
*P < 0.05 is considered significant.
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Page 8 of 11localization of developed neuron, and VLDLR II is the
important receptor binding Reelin in developed brain
and inducing Reelin signal transduction pathway
[30-32]. In addition, Martensen et al. found that VLDLR
II expressed by epithelial cancer cells could function in
the clearance of cell-surface-associated serine protei-
nase/serpin complexes in breast carcinomas [33]. We
had demonstrated that VLDLR II promotes SGC7901
cell migration and invasion by regulating the expression
of matrix metalloproteinase 2 (MMP2) and MMP9 [21].
Recently, we reported that uPA/PAI-1 complex can
increase VLDLR expression with promoted cell prolif-
eration and migration and stabilization of b-catenin [34].
To extend those studies, our interest is to evaluate the
relevance of VLDLR II expression with clinical
parameters in different human cancer tissues to charac-
terize its role in the cancer transformation progression.
In this research, we studied the expression levels of
VLDLR II in a large panel of human cancers and paired
normal tissues, since it is reported that VLDLR II is
expressed virtually in various cancers [13]. Our present
results show that VLDLR II expression in most cancer
tissues is higher than the corresponding, adjacent non-
affected control tissues. Specially, VLDLR II expression
in breast cancer is highest, followed by gastric and lung
cancer.
Patients are also classified on the basis of the most
common clinical features of each cancer. Interestingly,
some of these parameters correlated with increased
VLDLR II expression in cancer samples. For example,
Figure 4 Correlation of Western blot expression of VLDLR II with b-catenin in different cancers. A: Representative Western blot analyses
are shown of the VLDLR II and b-catenin expression in tissues from gastric, breast, and lung cancer patients (4 for each). B-D: Correlation of
Western blot expression of VLDLR II with b-catenin in different cancer tissues. Calculated regression lines also are shown on the correlation plots.
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Page 9 of 11the higher VLDLR II expression is associated with
lymph node metastasis, distant metastasis and advanced
TNM stage in breast and gastric cancer tissues. The
phenomenon showed that VLDLR II is closely related to
the metastasis progression of carcinoma. In breast can-
cer the presence of negative prognostic markers, such as
histological grade, generally correlate with higher
VLDLR II expression. In lung cancer, increased VLDLR
II expression also correlates with distant metastasis.
These results reveal the closer relationship of VLDLR II
expression with the clinicopathological guiding, up-regu-
lated VLDLR II expression may represent an clinical
marker in some cancers.
b-catenin is a key effector of the Wnt signaling path-
way, which binds members of the T-cell factor (TCF)/
lymphocyte enhancer binding factor (LEF) family of
transcription factors and activates target genes transcrip-
tion to be involved in development, tissue self-renewal
and cancer [35]. It also has been reported that VLDLR
can regulate the Wnt signaling, which has played an
important role in tumorgenesis. Silencing of VLDLR
expression by siRNA resulted in increased LRP5/6 levels
and b-catenin phosphorylation in cultured cells [19].
Moreover, we have demonstrated that the b-catenin
levels are associated with VLDLR II expression in
the cell culture models, which causes the elevation of
b-catenin levels and promotes cell proliferation and
migration through the activation of the b-catenin/TCF
signaling pathway [21]. In this study, we further detected
the expression of b-catenin by Western blot in human
cancer samples, the results show that b-catenin is higher
in cancer tissues. Especially, significant positive correla-
tions were found between VLDLR II and b-catenin in
gastric and breast cancers. The data strongly suggest
that there is a potential link between VLDLR II and
b-catenin signaling pathway.
In addition, to strengthen the relationship between
VLDLR II expression and metastasis, we have conducted
a tentative experiment on the expression level of vascu-
lar endothelial growth factor (VEGF), which was
regarded as a b-catenin target gene to play a important
role in angiogenesis and cancer metastasis progression
[36]. We found VLDLR II expression positively corre-
lated with VEGF in breast cancer samples with distant
metastasis (data not shown). We would like to carry out
more extensive experiment on this topic in order to
further intensify the knowledge of the relationship
between VLDLR II and cancer progression.
Conclusions
Together our findings indicate that VLDLR II may be
considered as an important role in the metastasis pro-
gression of cancers, which is overexpressed in different
human cancer types. To our knowledge, this is the first
evidence that VLDLR II gets involved in human cancer
metastasis at tissue levels. This study will help to thor-
oughly understand the function of VLDLR II and to
open new perspectives for diagnosis and treatment of a
wide range of cancers.
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